TScan Therapeutics Inc. (TCRX)
TCRX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/0001193125-26-089884-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TCRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001783328 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $10.3M |
| Net income | -$129.8M |
| Operating income | -$135.8M |
| Net margin | -1256.8% |
| Operating margin | -1315.4% |
| Revenue growth | +266.7% |
| Cash | $152.4M |
| Total assets | $228.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $73.0M cash; operating cash flow -$27.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 67,779,255 (2026-11-05); 56,747,993 a year earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-09-02 |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $146K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $586K | -$33.1M | -$27.1M | $73.0M | $33.0M | $5.2M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $1.1M | -$30.4M | -$27.5M | $100.2M | $32.8M | $7.1M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $982K | -$28.7M | -$24.3M | $128.1M | $32.7M | $9.1M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $2.6M | -$23.0M | -$32.0M | $152.4M | $32.5M | $10.3M | 10-K 2026-03-04 |
| Q3 2025 2025-09-30 | $2.5M | -$35.7M | -$32.5M | $169.5M | $32.4M | $8.4M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $3.1M | -$37.0M | -$33.3M | $169.4M | $32.3M | $7.0M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $2.2M | -$34.1M | -$37.6M | $154.1M | $32.2M | $4.4M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $665K | -$35.8M | -$27.4M | $178.7M | $32.1M | $2.8M | 10-K 2026-03-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-03-05 |
| Latest annual report | 10-K | 2026-03-04 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-10-26 |
Source: SEC EDGAR submissions feed, 336 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.4% |
| 1 month | -25.8% |
| 3 months | -79.1% |
| Year to date | -83.9% |
| 1 year | -85.8% |
| From 52-week high | -88.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INAB | IN8bio Inc. | $0.8160 | -0.49% | $8.8M |
| INTS | Intensity Therapeutics Inc. | $3.07 | -0.32% | $10.1M |
| ALGS | Aligos Therapeutics Inc. | $1.66 | -20.95% | $10.4M |
| SCLX | Scilex Holding Company | $1.25 | -12.59% | $10.6M |
| BCDA | BioCardia Inc. | $0.7901 | -4.92% | $12.0M |
| DYAI | Dyadic International Inc. | $0.3200 | -2.14% | $12.8M |
| JSPR | Jasper Therapeutics Inc. | $11.77 | -13.96% | $13.1M |
| PASG | Passage Bio Inc. | $4.13 | -2.82% | $13.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier